Enabling future drug discovery by de novo design

Wiley Interdisciplinary Reviews: Computational Molecular Science

Volumn 1, Issue 5, 2011, Pages 742-759

  Hartenfeller, Markus ^a   Schneider, Gisbert ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTER ASSISTED; DE NOVO DESIGN; DRUG DESIGN; DRUG DISCOVERY; MEDICINAL CHEMISTRY; MOLECULAR SCAFFOLDS; SYNTHESIZABILITY;

SCAFFOLDS;

CHEMICAL COMPOUNDS;

EID: 80053593946     PISSN: 17590876     EISSN: 17590884     Source Type: Journal    
DOI: 10.1002/wcms.49     Document Type: Review

References (132)

1. Schneider G, Baringhaus KH. Molecular Design-Concepts and Applications. New York/Weinheim: Wiley-VCH; 2008.
2. Loving K, Alberts I, Sherman W. Computational approaches for fragment-based and de novo design. Curr Top Med Chem 2010, 10:14-32.
3. Mayr LM, Bojanic D. Novel trends in high-throughput screening. Curr Opin Pharmacol 2009, 9:580-588.
4. Davies JW, Glick M, Jenkins JL. Streamlining lead discovery by aligning in silico and high-throughput screening. Curr Opin Chem Biol 2006, 10:343-351.
5. McInnes C. Virtual screening strategies in drug discovery. Curr Opin Chem Biol 2007, 11:494-502.
6. Rankovics Z, Morphy R, eds. Lead Generation Approaches in Drug Discovery. New York: John Wiley & Sons; 2010.
7. Klebe G. Virtual ligand screening: strategies, perspectives and limitations. Drug Discov Today 2006, 11:580-594.
8. Eglen RM, Schneider G, Böhm HJ. High-throughput screening and virtual screening: entry points to drug discovery. In: Schneider G, Böhm HJ, eds. Virtual Screening for Bioactive Molecules. New York/Weinheim: Wiley-VCH; 2000, 1-14.
9. Schneider G, Hartenfeller M, Proschak E. De novo design. In: Rankovic Z, Morphy R, eds. Lead Generation Approaches in Drug Discovery. New York: John Wiley & Sons; 2010, 165-185.
10. Schneider G, Fechner U. Computer-based de novo design of druglike molecues. Nat Rev Drug Discov 2005, 4:649-663.
11. Danziger DJ, Dean PM. Automated site-directed drug design: a general algorithm for knowledge acquisition about hydrogen-bonding regions at protein surfaces. Proc R Soc Lond B 1989, 236:101-113.
12. Lewis RA, Dean PM. Automated site-directed drug design: the concept of spacer skeletons for primary structure generation. Proc R Soc Lond B 1989, 236:125-140.
13. Lewis RA, Dean PM. Automated site-directed drug design: the formation of molecular templates in primary structure generation. Proc R Soc Lond B 1989, 236:141-162.
14. Gillett VA, Johnson AP, Mata P, Sike S. Automated structure design in 3D. Tetrahedron Comput Methodol 1990, 3:681-696.
15. Lewis RA, Roe DC, Huang C, Ferrin TE, Langridge R, Kuntz ID. Automated site-directed drug design using molecular lattices. J Mol Graph 1992, 10:66-78.
16. Böhm HJ. The computer program LUDI: a new simple method for the de-novo design of enzyme inhibitors. J Comput Aided Mol Des 1992, 6:61-78.
17. Böhm HJ. LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads. J Comput Aided Mol Des 1992, 6:593-606.
18. Böhm HJ. A novel computational tool for automated structure-based drug design. J Mol Recognit 1993, 6:131-137.
19. Böhm HJ. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J Comput Aided Mol Des 1994, 8:243-256.
20. Tschinke V, Cohen NC. The NEWLEAD program: a new method for the design of candidate structures from pharmacophoric hypothesis. J Med Chem 1993, 36:3863-3870.
21. Ho CMW, Marshall GR. SPLICE: a program to assemble partial query solutions from three-dimensional database searches into novel ligands. J Comput Aided Mol Des 1993, 7:623-647.
22. Rotstein SH, Murcko MA. GroupBuild: a fragment-based method for de novo drug design. J Med Chem 1993, 36:1700-1710.
23. Pearlman DA, Murcko MA. CONCEPTS: new dynamic algorithm for de novo design suggestion. J Comput Chem 1993, 14:1184-1193.
24. Gillet VJ, Johnson AP, Mata P, Sike S, Williams P. SPROUT: a program for structure generation. J Comput Aided Mol Des 1993, 7:127-153.
25. Gillet VJ, Newell W, Mata P, Myatt G, Sike S, Zsoldos Z, Johnson AP. SPROUT: recent developments in the de novo design of molecules. J Comput Aided Mol Des 1994, 34:207-217.
26. Mata P, Gillet VJ, Johnson AP, Lampreia J, Myatt GJ, Sike S, Stebbings AL. SPROUT: 3D structure generation using templates. J Chem Inf Comput Sci 1995, 35:479-493.
27. Eisen MB, Wiley DC, Karplus M, Hubbard RE. HOOK: a program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site. Proteins 1994, 19:199-221.
28. Miranker A, Karplus M. Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins 1991, 11:29-34.
29. Caflish A, Miranker A, Karplus M. Multiple copy simultaneous search and construction of ligands in binding sites: application to inhibitors of HIV-1 aspartic proteinase. J Med Chem 1993, 36:2142-2167.
30. Bohacek RS, McMartin C. Multiple highly diverse structures complementary to enzyme binding sites: results of extensive application of a de novo design method incorporating combinatorial growth. J Am Chem Soc 1994, 116:5560-5571.
31. Glen RC, Payne AWR. A genetic algorithm for the automated generation of molecules. J Comput Aided Mol Des 1995, 9:181-202.
32. Clark DE, Frenkel D, Levy SA, Li J, Murray CW, Robson B, Waszkowycz B, Westhead DR. PRO LIGAND: an approach to de novo molecular design. 1. Application to the design of organic molecules. J Comput Aided Mol Des 1995, 9:13-32.
33. Waszkowycz B, Clark DE, Frenkel D, Li J, Murray CW, Robson B, Westhead DR. PRO LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores. J Med Chem 1994, 37:3994-4002.
34. Westhead DR, Clark DE, Frenkel D, Li J, Murray CW, Robson B, Waszkowycz B. PRO LIGAND: an approach to de novo molecular design. 3. A genetic algorithm for structure refinement. J Comput Aided Mol Des 1995, 9:139-148.
35. Frenkel D, Clark DE, Li J, Murray CW, Robson B, Waszkowycz B, Westhead DR. PRO LIGAND: an approach de novo molecular design. 4. Application to the design of peptides. J Comput Aided Mol Des 1995, 9:213-225.
36. Clark DE, Murray CW. PRO LIGAND: an approach to de novo molecular design. 5. Tools for the Analysis of Generated Structures. J Chem Inf Comput Sci 1995, 35:914-923.
37. Murray CW, Clark DE, Byrne DG. PRO LIGAND: an approach to de novo molecular design. 6. Flexible fitting in the design of peptides. J Comput Aided Mol Des 1995, 9:381-395.
38. DeWitte RS, Shakhnovich EI. SMoG de novo design method based on simple, fast, and accurate free energy estimates. 1. Methodology and supporting evidence. J Am Chem Soc 1996, 118:11733-11744.
39. Ishchenko AV, Shakhnovich EI. SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions. J Med Chem 2002, 45:2770-2780.
40. Pearlman DA, Murcko MA. CONCERTS: dynamic connection of fragments as an approach to de novo ligand design. J Med Chem 1996, 39:1651-1663.
41. Luo Z, Wang R, Lai L. RASSE: a new method for structure-based drug design. J Chem Inf Comput Sci 1996, 36:1187-1194.
42. Grzybowski BA, Ishchenko AV, Kim CY, Topalov G, Chapman R, Christianson DW, Whitesides GM, Shakhnovich EI. Combinatorial computational method gives new picomolar ligands for a known enzyme. Proc Natl Acad Sci USA 2002, 99:1270-1273.
43. Todorov NP, Dean PM. Evaluation of a method for controlling molecular scaffold diversity in de novo ligand design. J Comput Aided Mol Des 1997, 11:175-192.
44. Todorov NP, Dean PM. A branch-and-bound method for optimal atom-type assignment in de novo ligand design. J Comput Aided Mol Des 1998, 12:335-350.
45. Murray CW, Clark DE, Auton TR, Firth MA, Li J, Sykes RA, Waszkowycz B, Westhead DR, Young SC. PRO_SELECT: combining structure-based drug design and combinatorial chemistry for rapid lead discovery. 1. Technology. J Comput Aided Mol Des 1997, 11:193-207.
46. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 1997, 11:425-445.
47. Stahl M, Todorov NP, James T, Mauser H, Böhm HJ, Dean PM. A validation study on the practical use of automated de novo design. J Comput Aided Mol Des 2002, 16:459-478.
48. Nachbar RB. Molecular evolution: a hierarchical representation for chemical topology and its automated manipulation. Proc 3rd Annu Gen Program Conf 1998, 246-253.
49. Nachbar RB. Molecular evolution: automated manipulation of hierarchical chemical topology and its application to average molecular structures. Gen Program Evolvable Mach 2000, 1:57-94.
50. Globus A, Lawton J, Wipke WT. Automatic Molecular design using evolutionary algorithms. Nanotechnology 1999, 10:290-299.
51. Liu H, Duan Z, Luo Q, Shi Y. Structure-based ligand design by dynamically assembling molecular building blocks at binding site. Proteins 1999, 36:462-470.
52. Wang R, Gao Y, Lai L. LigBuilder: a multi-purpose program for structure-based drug design. J Mol Model 2000, 6:498-516.
53. Schneider G, Lee ML, Stahl M, Schneider P. de novo design of molecular architectures by evolutionary assembly of drug-derived building blocks. J Comput Aided Mol Des 2000, 14:487-494.
54. Schneider G, Clément-Chomienne O, Hilfiger L, Schneider P, Kirsch S, Böhm HJ, Neidhart W. Virtual screening for bioactive molecules by evolutionary de novo design. Angew Chem Int Ed 2000, 39:4130-4133.
55. Zhu J, Yu H, Fan H, Liu H, Shi Y. Design of selective inhibitors of cyclooxygenase-2 dynamic assembly of molecular building blocks. J Comput Aided Mol Des 2001, 15:447-463.
56. Douguet D, Thoreau E, Grassy G. A genetic algorithm for the automated generation of small organic molecules: drug design using an evolutionary algorithm. J Comput Aided Mol Des 2000, 14:449-466.
57. Pellegrini E, Field MJ. Development and testing of a de novo drug-design algorithm. J Comput Aided Mol Des 2003, 17:621-641.
58. Vinkers HM, de Jonge MR, Daeyaert FF, Heeres J, Koymans LM, van Lenthe JH, Lewi PJ, Timmerman H, van Aken K, Janssen PA. SYNOPSIS: SYNthesize and OPtimize System In Silico. J Med Chem 2003, 46:2765-2773.
59. Zhu J, Fan H, Liu H, Shi Y. Structure-based ligand design for flexible proteins: application of new F-DycoBlock. J Comput Aided Mol Des 2001, 15:979-996.
60. Pierce AC, Rao G, Bemis GW. BREED: generating novel inhibitors through hybridization of known ligands. Application to CDK2, P38, and HIV protease. J Med Chem 2004, 47:2768-2775.
61. Nikitin S, Zaitseva N, Demina O, Solovieva V, Mazin E, Mikhalev S, Smolov M, Rubinov A, Vlasov P, Lepikhin D, et al. A very large diversity space of synthetically accessible compounds for use with drug design programs. J Comput Aided Mol Des 2005, 19:47-63.
62. Pegg SCH, Haresco JJ, Kuntz ID. A genetic algorithm for structure-based de novo design. J Comput Aided Mol Des 2001, 15:911-933.
63. Fechner U, Schneider G. Flux (1): a virtual synthesis scheme for fragment-based de novo design. J Chem Inf Model 2006, 46:699-707.
64. Fechner U, Schneider G. Flux (2): comparison of molecular mutation and crossover operators for ligand-based de novo design. J Chem Inf Model 2007, 47:656-667.
65. Degen J, Rarey M. FlexNovo: structure-based searching in large fragment spaces. ChemMedChem 2006, 1:854-868.
66. Brown N, McKay B, Gilardoni F, Gasteiger J. A graph-based genetic algorithm and its application to the multiobjective evolution of median molecules. J Chem Inf Comput Sci 2004, 44:1079-1087.
67. Dey F, Caflisch A. Fragment-based de novo ligand design by multiobjective evolutionary optimization. J Chem Inf Model 2008, 48:679-690.
68. Hartenfeller M, Proschak E, Schüller A, Schneider G. Concept of combinatorial de novo design of druglike molecules by particle swarm optimization. Chem Biol Drug Des 2008, 72:16-26.
69. Proschak E, Sander K, Zettl H, Tanrikulu Y, Rau O, Schneider P, Schubert-Zsilavecz M, Stark H, Schneider G. From molecular shape to potent bioactive agents. II. Fragment-based de novo design. ChemMedChem 2009, 4:45-48.
70. Douguet D, Munier-Lehmann H, Labesse G, Pochet S. LEA3D: a computer-aided ligand design for structure-based drug design. J Med Chem 2005, 48:2457-2468.
71. Feher M, Gao Y, Baber C, Shirley WA, Saunders J. The use of ligand-based de novo design for scaffold hopping and sidechain optimization: two case studies. Bioorg Med Chem 2008, 16:422-427.
72. Proschak E, Zettl H, Tanrikulu Y, Weisel M, Kriegl JM, Rau O, Schubert-Zsilavecz M, Schneider G. From molecular shape to potent bioactive agents. I. Bioisosteric replacement of molecular fragments. ChemMedChem 2009, 4:41-44.
73. Hecht D, Fogel GB. A novel in silico approach to drug discovery via computational intelligence. J Chem Inf Model 2009, 49:1105-1121.
74. Kutchukian PS, Lou D, Shakhnovich EI. FOG: Fragment Optimized Growth algorithm for the de novo generation of molecules occupying druglike chemical space. J Chem Inf Model 2009, 49:1630-1642.
75. Nisius B, Rester U. Fragment shuffling: an automated workflow for three-dimensional fragment-based ligand design. J Chem Inf Model 2009, 49:1211-1222.
76. Moriaud F, Doppelt-Azeroual O, Martin L, Oguievetskaia K, Koch K, Vorotyntsev A, Adcock SA, Delfaud F. Computational fragment-based approach at PDB scale by protein local similarity. J Chem Inf Model 2009, 49:280-294.
77. Damewood JR, Lerman CL, Masek BB. NovoFLAP: a ligand-based de novo design approach for the generation of medicinally relevant ideas. J Chem Inf Model 2010, 50:1296-1303.
78. Huang Q, Li LL, Yang SJ. PhDD: a new pharmacophore-based de novo design method of drug-like molecules combined with assessment of synthetic accessibility. J Mol Graph Model 2010, 28:775-787.
79. Nicolaou CA, Apostolakis J, Pattichis CS. de novo drug design using multiobjective evolutionary graphs. J Chem Inf Model 2009, 49:295-307.
80. Hartenfeller M, Schneider G. de novo drug design. Methods Mol Biol 2011, 672:299-323.
81. Wise A, Gearing K, Rees S. Target validation of G-protein coupled receptors. Drug Discov Today 2002, 7:235-246.
82. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi H, Kuhn P, Weis WI, Kobilka BK, et al. High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science 2007, 318:1258-1265.
83. Rechenberg I. Evolutionsstrategie-Optimierung technischer Systeme nach Prinzipien der biologischen Evolution. Stuttgart: Frommann-Holzboog; 1973.
84. Johnson MA, Maggiora GM, eds. Concepts and Applications of Molecular Similarity. New York: John Wiley & Sons; 1990.
85. Maggiora GM. On outliers and activity cliffs-why QSAR often disappoints. J Chem Inf Model 2006, 46:1535.
86. Horvath D, Jeandenans C. Neighborhood behavior of in silico structural spaces with respect to in vitro activity spaces-a novel understanding of the molecular similarity principle in the context of multiple receptor binding profiles. J Chem Inf Comput Sci 2003, 43:680-690.
87. Kolb P, Irwin JJ. Docking screens: right for the right reasons? Curr Top Med Chem 2009, 9:755-770.
88. Zhong S, Zhang Y, Xiu Z. Rescoring ligand docking poses. Curr Opin Drug Discov Devel 2010, 13:326-334.
89. Schneider G, Böhm HJ. Virtual screening and fast automated docking methods. Drug Discov Today 2002, 7:64-70.
90. Höltje HD, Sippl W, Rognan G, Folkers G. Molecular Modeling. Basic Principles and Applications. 3rd ed. Weinheim: Wiley-VCH; 2008.
91. Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996, 261:470-489.
92. Gohlke H, Hendlich M, Klebe G. Predicting binding modes, binding affinities and 'hot spots' for protein-ligand complexes using a knowledge-based scoring function. Perspect Drug Discov Des 2000 20:115-144.
93. Gohlke H, Hendlich M, Klebe G. Knowledge-based scoring function to predict protein-ligand interactions. J Mol Biol 2000, 295:337-356.
94. Langer T. Pharmacophores in drug research. Mol Inf 2010, 29:470-475.
95. Lloyd DG, Buenemann CL, Todorov NP, Manallack DT, Dean PM. Scaffold hopping in de novo design. Ligand generation in the absence of receptor information. J Med Chem 2004, 47:493-496.
96. Tanrikulu Y, Schneider G. Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening. Nat Rev Drug Discov 2008, 7:667-677.
97. Gillett VJ, Myatt G, Zsoldos Z, Johnson AP. SPROUT, HIPPO and CAESA: tools for de novo structure generation and estimation of synthetic accessibility. Perspect Drug Discov Des 1995, 3:34-50.
98. Böhm HJ. Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs. J Comput Aided Mol Des 1998, 12:309-323.
99. Durrant JD, Amaro RE, McCammon JA. AutoGrow: a novel algorithm for protein inhibitor design. Chem Biol Drug Des 2009, 73:168-78.
100. Kutchukian PS, Shakhnovich EI. de novo design: balancing novelty and confined chemical space. Exp Opin Drug Discov 2010, 5:789-812.
101. Markov AA. Extension of the limit theorems of probability theory to a sum of variables connected in a chain. In: Howard R, ed. Dynamic Probabilistic Systems, Volume 1, Markov Chains. New York: John Wiley & Sons; 1971.
102. Lewell XQ, Judd D, Watson S, Hann M. RECAP-retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J Chem Inf Comput Sci 1998, 38:511-522.
103. Daylight Chemical Information Systems, Inc., 120 Vantis-Suite 550, Aliso Viejo, CA 92656, USA.
104. Symyx Technology Inc., 2440 Camino Ramon, Suite 300, San Ramon, CA 94583, USA.
105. Patel H, Bodkin MJ, Chen B, Gillet VJ. Knowledge-based approach to de novo design using reaction vectors. J Chem Inf Model 2009, 49:1163-1184.
106. Pfeffer P, Fober T, Hüllermeier E, Klebe G. GARLig: a fully automated tool for subset selection of large fragment spaces via a self-adaptive genetic algorithm. J Chem Inf Model 2010, 50:1644-1659.
107. Bohacek RS, McMartin C, Guida WC. The art and practice of structure-based drug design: a molecular modeling perspective. Med Res Rev 1996, 16:3-50.
108. Peltason L, Bajorath J. SAR index: quantifying the nature of structure-activity relationships. J Med Chem 2007, 50:5571-5578.
109. Schneider G, Schüller A. Adaptive combinatorial design of focused compound libraries. Methods Mol Biol 2009, 572:135-147.
110. Metropolis N, Rosenbluth AW, Rosenbluth MN, Teller AH, Teller E. Equation of state calculations by fast computing machines. J Chem Phys 1953, 21:1087-1092.
111. Altekar G, Dwarkadas S, Huelsenbeck J, Ronquist F. Parallel metropolis coupled Markov chain Monte Carlo for Bayesian phylogenetic inference. Bioinformatics 2004, 20:407-415.
112. Guo M, Liu Y, Malec J. A new Q-learning algorithm based on the Metropolis criterion. IEEE Trans Syst Man Cybern Part B 2004, 34:2140-2143.
113. Hiss JA, Hartenfeller M, Schneider G. Concepts and applications of 'natural computing' techniques in de novo drug and peptide design. Curr Pharm Des 2010, 16:1656-1665.
114. Kennedy J, Eberhart RC. Particle swarm optimization. Proc IEEE Int Conf Neur Netw 1995:1942-1948.
115. Cormen TH, Leiserson CE, Rivest RL. Greedy algorithms. In: Introduction to Algorithms. Cambridge, MA: MIT Press; 1990.
116. Lessel U, Wellenzohn B, Lilienthal M, Claussen H. Searching fragment spaces with feature trees. J Chem Inf Model 2009, 49:270-279.
117. Klebe G, Böhm HJ. Energetic and entropic factors determining binding affinity in protein-ligand complexes. J Rec Signal Transduct Res 1997, 17:459-473.
118. Gillet VJ, Khatib W, Willett P, Fleming PJ, Green DV. Combinatorial library design using a multiobjective genetic algorithm. J Chem Inf Comput Sci 2002, 42:375-385.
119. Brown N, McKay B, Gasteiger J. The de novo design of median molecules within a property range of interest. J Comput Aided Mol Des 2004, 18:761-771.
120. Boda K, Seidel T, Gasteiger J. Structure and reaction based evaluation of synthetic accessibility. J Comput Aided Mol Des 2007, 21:311-325.
121. Law J, Zsoldos Z, Simon A, Reid D, Liu Y, Khew SY, Johnson AP, Major S, Wade RA, Ando HY. Route designer: a retrosynthetic analysis tool utilizing automated retrosynthetic rule generation. J Chem Inf Model 2009, 49:593-602.
122. Herschhorn A, Lerman L, Weitman M, Gleenberg IO, Nudelman A, Hizi A. de novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants. J Med Chem 2007, 50:2370-2384.
123. Frey KM, Georgiev I, Donald BR, Anderson AC. Predicting resistance mutations using protein design algorithms. Proc Natl Acad Sci USA 2010, 107:13707-13712.
124. Clegg NJ, Paruthiyil S, Leitman DC, Scanlan TS. Differential response of estrogen receptor subtypes to 1, 3-diarylindene and 2, 3-diarylindene ligands. J Med Chem 2005, 48:5989-6003.
125. Schneider G, Neidhart W, Giller T, Schmid G. Scaffold-hopping by topological pharmacophore search: a contribution to virtual screening. Angew Chem Int Ed 1999, 38:2894-2896.
126. Jorgensen WL, Ruiz-Caro J, Tirado-Rives J, Basavapathruni A, Anderson KS, Hamilton AD. Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2006, 16:663-667.
127. Maass P, Schulz-Gasch T, Stahl M, Rarey M. Recore: a fast and versatile method for scaffold hopping based on small molecule crystal structure conformations. J Chem Inf Model 2007, 47:390-399.
128. Hay BP, Oliferenko AA, Uddin J, Zhang C, Firman TK. Search for improved host architectures: application of de novo structure-based design and high-throughput screening methods to identify optimal building blocks for multidentate ethers. J Am Chem Soc 2005, 127:17043-17053.
129. Firth-Clark S, Willems HM, Williams A, Harris W. Generation and selection of novel estrogen receptor ligands using the de novo structure-based design tool SkelGen. J Chem Inf Model 2006, 46:642-647.
130. Firth-Clark S, Kirton SB, Willems HM, Williams A. de novo ligand design to partially flexible active sites: application of the ReFlex algorithm to carboxypeptidase A, acetylcholinesterase, and the estrogen receptor. J Chem Inf Model 2008, 48:296-305.
131. Kandil S, Biondaro S, Vlachakis D, Cummins AC, Coluccia A, Berry C, Leyssen P, Neyts J, Brancale A. Discovery of a novel HCV helicase inhibitor by a de novo drug design approach. Bioorg Med Chem Lett 2009, 19:2935-2937.
132. Schneider G, Geppert T, Hartenfeller M, Reisen F, Klenner A, Reutlinger M, Haehnke V, Hiss JA, Zettl H, Keppner S, et al. Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors. Future Med Chem 2011, 3:415-424.